BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Bevacizumab|DRUG: Standard adjuvant chemotherapy
Sponsor: Hoffmann-La Roche